NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, Price Target & More

$6.60 +0.06 (+0.92 %)
(As of 04/20/2018 12:12 PM ET)
Previous Close$6.54
Today's Range$6.40 - $6.61
52-Week Range$2.28 - $9.75
Volume88,646 shs
Average Volume821,770 shs
Market Capitalization$361.37 million
P/E RatioN/A
Dividend YieldN/A
Beta1.71

About Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals logoPieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company's second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Receive PIRS News and Ratings via Email

Sign-up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PIRS
CUSIPN/A
Phone857-246-8998

Debt

Debt-to-Equity RatioN/A
Current Ratio1.96%
Quick Ratio1.96%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.27 million
Price / Sales14.06
Cash FlowN/A
Price / CashN/A
Book Value$0.26 per share
Price / Book25.38

Profitability

EPS (Most Recent Fiscal Year)($0.40)
Net Income$-17,640,000.00
Net Margins-69.82%
Return on Equity-162.54%
Return on Assets-19.05%

Miscellaneous

Employees68
Outstanding Shares53,850,000

How to Become a New Pot Stock Millionaire

Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) issued its earnings results on Friday, March, 9th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.04) by $0.21. The biotechnology company had revenue of $18.15 million for the quarter, compared to analysts' expectations of $7.63 million. Pieris Pharmaceuticals had a negative return on equity of 162.54% and a negative net margin of 69.82%. View Pieris Pharmaceuticals' Earnings History.

What price target have analysts set for PIRS?

5 equities research analysts have issued 12-month price objectives for Pieris Pharmaceuticals' shares. Their forecasts range from $9.00 to $13.00. On average, they expect Pieris Pharmaceuticals' share price to reach $11.50 in the next year. View Analyst Ratings for Pieris Pharmaceuticals.

Are investors shorting Pieris Pharmaceuticals?

Pieris Pharmaceuticals saw a increase in short interest in March. As of March 15th, there was short interest totalling 2,774,289 shares, an increase of 58.2% from the February 28th total of 1,753,784 shares. Based on an average trading volume of 1,111,459 shares, the days-to-cover ratio is currently 2.5 days. Currently, 5.5% of the company's stock are short sold.

Who are some of Pieris Pharmaceuticals' key competitors?

Who are Pieris Pharmaceuticals' key executives?

Pieris Pharmaceuticals' management team includes the folowing people:
  • James A. Geraghty, Chairman of the Board (Age 62)
  • Stephen S. Yoder, President, Chief Executive Officer, Director (Age 39)
  • Lance E. Thibault, Acting Chief Financial Officer (Age 50)
  • Claude Knopf, Senior Vice President, Chief Business Officer
  • Louis A. Matis M.D., Senior Vice President and Chief Development Officer (Age 54)
  • Julian Adams, Director (Age 61)
  • Jean-Pierre Bizzari M.D., Director (Age 62)
  • Christopher P. Kiritsy, Director (Age 49)
  • Steven Prelack, Independent Director (Age 57)
  • Michael Richman, Independent Director (Age 54)

Has Pieris Pharmaceuticals been receiving favorable news coverage?

Press coverage about PIRS stock has been trending somewhat positive on Friday, according to Accern. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Pieris Pharmaceuticals earned a daily sentiment score of 0.04 on Accern's scale. They also gave news articles about the biotechnology company an impact score of 46.33 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $6.60.

How big of a company is Pieris Pharmaceuticals?

Pieris Pharmaceuticals has a market capitalization of $361.37 million and generates $25.27 million in revenue each year. The biotechnology company earns $-17,640,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Pieris Pharmaceuticals employs 68 workers across the globe.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]


MarketBeat Community Rating for Pieris Pharmaceuticals (PIRS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  137 (Vote Outperform)
Underperform Votes:  104 (Vote Underperform)
Total Votes:  241
MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe PIRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PIRS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pieris Pharmaceuticals (NASDAQ:PIRS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Pieris Pharmaceuticals in the last 12 months. Their average twelve-month price target is $11.50, suggesting that the stock has a possible upside of 74.24%. The high price target for PIRS is $13.00 and the low price target for PIRS is $9.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.50$11.00$10.00$9.00
Price Target Upside: 74.24% upside54.93% upside44.51% upside70.45% upside

Pieris Pharmaceuticals (NASDAQ:PIRS) Consensus Price Target History

Price Target History for Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals (NASDAQ:PIRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018Evercore ISIInitiated CoverageOutperform -> Outperform$13.00HighView Rating Details
3/19/2018Jefferies GroupInitiated CoverageBuy -> Buy$12.00HighView Rating Details
3/9/2018HC WainwrightReiterated RatingBuy$12.00HighView Rating Details
1/17/2018William BlairInitiated CoverageOutperformHighView Rating Details
5/30/2017Rodman & RenshawInitiated CoverageBuy -> Buy$9.00HighView Rating Details
4/12/2017OppenheimerSet Price TargetBuy$9.00LowView Rating Details
9/28/2016Roth CapitalReiterated RatingBuy$6.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Pieris Pharmaceuticals (NASDAQ:PIRS) Earnings History and Estimates Chart

Earnings by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals (NASDAQ:PIRS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.61)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.23)$0.36($0.01)
Q2 20183($0.22)($0.17)($0.20)
Q3 20183($0.21)($0.18)($0.20)
Q4 20183($0.22)($0.19)($0.21)

Pieris Pharmaceuticals (NASDAQ PIRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2018Q4 2017($0.04)$0.17$7.63 million$18.15 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.21)($0.1590)$1.52 million$3.93 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.14)($0.23)$3.75 million$1.85 millionViewN/AView Earnings Details
5/10/2017Q1 2017$0.16($0.19)$32.30 million$1.34 millionViewN/AView Earnings Details
3/22/2017Q4 2016($0.13)($0.16)$1.10 million$2.73 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.13)($0.14)$1.12 million$0.79 millionViewN/AView Earnings Details
8/10/2016Q216($0.15)($0.14)$1.08 million$1.07 millionViewN/AView Earnings Details
5/11/2016Q116($0.12)($0.10)$6.40 million$1.25 millionViewN/AView Earnings Details
3/23/2016Q415($0.12)($0.07)$3.27 million$2.14 millionViewN/AView Earnings Details
11/11/2015Q315($0.11)($0.10)$0.23 million$0.42 millionViewN/AView Earnings Details
8/12/2015Q215($0.14)($0.12)$0.25 million$0.16 millionViewN/AView Earnings Details
5/13/2015Q1 2015($0.19)($0.13)$1.00 million$0.22 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Pieris Pharmaceuticals (NASDAQ:PIRS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Pieris Pharmaceuticals (NASDAQ PIRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.05%
Institutional Ownership Percentage: 43.99%
Insider Trading History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Institutional Ownership by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals (NASDAQ PIRS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Orbimed Advisors LlcMajor ShareholderSell7,897$8.98$70,915.06View SEC Filing  
1/3/2018Orbimed Advisors LlcMajor ShareholderSell1,709,620$7.35$12,565,707.00View SEC Filing  
12/18/2017Orbimed Advisors LlcMajor ShareholderSell147,635$5.70$841,519.50View SEC Filing  
8/17/2017Allan ReineInsiderBuy65,000$4.82$313,300.0045,000View SEC Filing  
8/17/2017James A GeraghtyDirectorBuy10,000$4.82$48,200.0010,000View SEC Filing  
6/14/2016Louis MatisSVPBuy10,000$1.70$17,000.002,085View SEC Filing  
6/13/2016Darlene M Deptula-HicksCFOBuy5,000$1.66$8,300.005,000View SEC Filing  
6/13/2016Stephen S YoderCEOBuy6,000$1.68$10,080.006,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pieris Pharmaceuticals (NASDAQ PIRS) News Headlines

Source:
DateHeadline
National Research (NRCIA) & Pieris Pharmaceuticals (PIRS) Financial ReviewNational Research (NRCIA) & Pieris Pharmaceuticals (PIRS) Financial Review
www.americanbankingnews.com - April 18 at 11:06 PM
Pieris Pharmaceuticals (PIRS) vs. National Research (NRCIB) Financial SurveyPieris Pharmaceuticals (PIRS) vs. National Research (NRCIB) Financial Survey
www.americanbankingnews.com - April 18 at 5:27 AM
BidaskClub Downgrades Pieris Pharmaceuticals (PIRS) to BuyBidaskClub Downgrades Pieris Pharmaceuticals (PIRS) to Buy
www.americanbankingnews.com - April 15 at 10:34 PM
Head-To-Head Survey: Pieris Pharmaceuticals (PIRS) vs. Exelixis (EXEL)Head-To-Head Survey: Pieris Pharmaceuticals (PIRS) vs. Exelixis (EXEL)
www.americanbankingnews.com - April 12 at 1:09 PM
Pieris Pharmaceuticals Inc (PIRS) Expected to Announce Quarterly Sales of $11.39 MillionPieris Pharmaceuticals Inc (PIRS) Expected to Announce Quarterly Sales of $11.39 Million
www.americanbankingnews.com - April 11 at 1:44 AM
Zacks: Brokerages Expect Pieris Pharmaceuticals Inc (PIRS) Will Announce Earnings of -$0.02 Per ShareZacks: Brokerages Expect Pieris Pharmaceuticals Inc (PIRS) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - April 9 at 11:15 PM
HC Wainwright Analysts Give Pieris Pharmaceuticals (PIRS) a $9.00 Price TargetHC Wainwright Analysts Give Pieris Pharmaceuticals (PIRS) a $9.00 Price Target
www.americanbankingnews.com - April 6 at 4:17 PM
Pieris Pharmaceuticals Inc (PIRS) Given Consensus Rating of "Buy" by BrokeragesPieris Pharmaceuticals Inc (PIRS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 5 at 3:34 PM
Pieris Pharmaceuticals (PIRS) Cut to Sell at BidaskClubPieris Pharmaceuticals (PIRS) Cut to Sell at BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM
Pieris Pharmaceuticals (PIRS) Raised to Buy at ValuEnginePieris Pharmaceuticals (PIRS) Raised to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 10:43 AM
Short Interest in Pieris Pharmaceuticals Inc (PIRS) Expands By 58.2%Short Interest in Pieris Pharmaceuticals Inc (PIRS) Expands By 58.2%
www.americanbankingnews.com - March 30 at 4:01 AM
Pieris Pharmaceuticals (PIRS) Price Target Raised to $12.00 at HC WainwrightPieris Pharmaceuticals (PIRS) Price Target Raised to $12.00 at HC Wainwright
www.americanbankingnews.com - March 28 at 3:12 PM
Pieris Pharmaceuticals (PIRS) Now Covered by Analysts at William BlairPieris Pharmaceuticals (PIRS) Now Covered by Analysts at William Blair
www.americanbankingnews.com - March 27 at 7:27 PM
Pieris Pharmaceuticals (PIRS) Upgraded at BidaskClubPieris Pharmaceuticals (PIRS) Upgraded at BidaskClub
www.americanbankingnews.com - March 25 at 2:34 PM
$11.39 Million in Sales Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter$11.39 Million in Sales Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter
www.americanbankingnews.com - March 25 at 3:46 AM
-$0.02 EPS Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter-$0.02 EPS Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter
www.americanbankingnews.com - March 23 at 11:14 PM
Pieris Pharmaceuticals Inc (PIRS) Expected to Post Q1 2018 Earnings of $0.36 Per SharePieris Pharmaceuticals Inc (PIRS) Expected to Post Q1 2018 Earnings of $0.36 Per Share
www.americanbankingnews.com - March 21 at 7:00 AM
Pieris Pharmaceuticals (PIRS) Now Covered by Analysts at Jefferies GroupPieris Pharmaceuticals (PIRS) Now Covered by Analysts at Jefferies Group
www.americanbankingnews.com - March 19 at 5:34 PM
Pieris Pharmaceuticals (PIRS) Now Covered by Evercore ISIPieris Pharmaceuticals (PIRS) Now Covered by Evercore ISI
www.americanbankingnews.com - March 19 at 9:13 AM
Pieris Pharma (PIRS) Defended at JMP Securities, Sees Weakness as Buying Opportunity - StreetInsider.comPieris Pharma (PIRS) Defended at JMP Securities, Sees Weakness as Buying Opportunity - StreetInsider.com
www.streetinsider.com - March 19 at 8:23 AM
Edited Transcript of PIRS earnings conference call or presentation 9-Mar-18 1:00pm GMTEdited Transcript of PIRS earnings conference call or presentation 9-Mar-18 1:00pm GMT
finance.yahoo.com - March 18 at 8:18 AM
BidaskClub Downgrades Pieris Pharmaceuticals (PIRS) to HoldBidaskClub Downgrades Pieris Pharmaceuticals (PIRS) to Hold
www.americanbankingnews.com - March 17 at 6:23 AM
Pieris Pharmaceuticals Inc (PIRS) Receives Consensus Recommendation of "Buy" from AnalystsPieris Pharmaceuticals Inc (PIRS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 11 at 5:54 PM
Pieris Pharmaceuticals (PIRS) Buy Rating Reaffirmed at HC WainwrightPieris Pharmaceuticals' (PIRS) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - March 9 at 9:02 PM
Pieris Pharmaceuticals Inc (PIRS) Expected to Post Quarterly Sales of $7.63 MillionPieris Pharmaceuticals Inc (PIRS) Expected to Post Quarterly Sales of $7.63 Million
www.americanbankingnews.com - March 8 at 3:30 AM
-$0.04 EPS Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter-$0.04 EPS Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter
www.americanbankingnews.com - March 6 at 7:18 PM
Pieris Pharmaceuticals to Present at Investor Conferences in MarchPieris Pharmaceuticals to Present at Investor Conferences in March
finance.yahoo.com - March 6 at 5:40 PM
446,371 Shares in Pieris Pharmaceuticals Inc (PIRS) Acquired by Arrowstreet Capital Limited Partnership446,371 Shares in Pieris Pharmaceuticals Inc (PIRS) Acquired by Arrowstreet Capital Limited Partnership
www.americanbankingnews.com - March 6 at 4:34 AM
Bogle Investment Management L P DE Raises Holdings in Pieris Pharmaceuticals Inc (PIRS)Bogle Investment Management L P DE Raises Holdings in Pieris Pharmaceuticals Inc (PIRS)
www.americanbankingnews.com - March 5 at 5:42 AM
Pieris Pharmaceuticals Inc (PIRS) Short Interest Up 92.8% in FebruaryPieris Pharmaceuticals Inc (PIRS) Short Interest Up 92.8% in February
www.americanbankingnews.com - March 3 at 1:54 AM
Pieris Pharmaceuticals to Host Full-Year 2017 Investor Call and Corporate Update on March 9, 2018Pieris Pharmaceuticals to Host Full-Year 2017 Investor Call and Corporate Update on March 9, 2018
finance.yahoo.com - February 28 at 6:03 PM
 Analysts Anticipate Pieris Pharmaceuticals Inc (PIRS) Will Announce Quarterly Sales of $7.63 Million Analysts Anticipate Pieris Pharmaceuticals Inc (PIRS) Will Announce Quarterly Sales of $7.63 Million
www.americanbankingnews.com - February 20 at 11:32 AM
Pieris Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare ConferencePieris Pharmaceuticals to Present at the RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 19 at 5:09 PM
BidaskClub Lowers Pieris Pharmaceuticals (PIRS) to BuyBidaskClub Lowers Pieris Pharmaceuticals (PIRS) to Buy
www.americanbankingnews.com - February 17 at 11:40 AM
Pieris Pharmaceuticals (PIRS) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowPieris Pharmaceuticals (PIRS) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 5:17 PM
Stock Traders Buy Large Volume of Pieris Pharmaceuticals Put Options (PIRS)Stock Traders Buy Large Volume of Pieris Pharmaceuticals Put Options (PIRS)
www.americanbankingnews.com - February 16 at 6:58 AM
Pieris Pharmaceuticals Inc (PIRS) Major Shareholder Orbimed Advisors Llc Sells 7,897 SharesPieris Pharmaceuticals Inc (PIRS) Major Shareholder Orbimed Advisors Llc Sells 7,897 Shares
www.americanbankingnews.com - February 15 at 10:04 PM
Pieris Pharma (PIRS) Prices 5.5M Share Common Offering at $8/ShPieris Pharma (PIRS) Prices 5.5M Share Common Offering at $8/Sh
www.streetinsider.com - February 15 at 9:19 AM
Pieris Pharma (PIRS) Plans Public Offering of Common StockPieris Pharma (PIRS) Plans Public Offering of Common Stock
www.streetinsider.com - February 14 at 9:52 AM
Pieris Pharmaceuticals Announces Public Offering of Common StockPieris Pharmaceuticals Announces Public Offering of Common Stock
finance.yahoo.com - February 14 at 9:52 AM
Pieris Pharmaceuticals Announces Pricing of its Public OfferingPieris Pharmaceuticals Announces Pricing of its Public Offering
finance.yahoo.com - February 14 at 9:52 AM
Seattle Genetics (SGEN), Pieris Pharmaceuticals (PIRS) Announce Multi-Program Immuno-Oncology Pact - StreetInsider.comSeattle Genetics (SGEN), Pieris Pharmaceuticals (PIRS) Announce Multi-Program Immuno-Oncology Pact - StreetInsider.com
www.streetinsider.com - February 11 at 3:55 PM
Pieris Pharmaceuticals: Management Continues To Execute - Seeking AlphaPieris Pharmaceuticals: Management Continues To Execute - Seeking Alpha
seekingalpha.com - February 11 at 3:55 PM
Pieris Pharmaceuticals (PIRS) Given a $12.00 Price Target at HC WainwrightPieris Pharmaceuticals (PIRS) Given a $12.00 Price Target at HC Wainwright
www.americanbankingnews.com - February 9 at 2:16 PM
Why Pieris Pharmaceuticals Inc. Is Soaring TodayWhy Pieris Pharmaceuticals Inc. Is Soaring Today
www.fool.com - February 9 at 12:59 PM
Pieris Pharmaceuticals Inc to Post Q1 2018 Earnings of ($0.15) Per Share, William Blair Forecasts (PIRS)Pieris Pharmaceuticals Inc to Post Q1 2018 Earnings of ($0.15) Per Share, William Blair Forecasts (PIRS)
www.americanbankingnews.com - February 9 at 8:00 AM
Pieris Pharmaceuticals (PIRS) Rating Increased to Hold at ValuEnginePieris Pharmaceuticals (PIRS) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - February 4 at 5:35 PM
Is Pieris Pharmaceuticals Inc (NASDAQ:PIRS) As Financially Strong As Its Balance Sheet Indicates?Is Pieris Pharmaceuticals Inc (NASDAQ:PIRS) As Financially Strong As Its Balance Sheet Indicates?
finance.yahoo.com - February 2 at 3:48 PM
Pieris Pharmaceuticals to Host Key Opinion Leader Event on February 6thPieris Pharmaceuticals to Host Key Opinion Leader Event on February 6th
finance.yahoo.com - January 29 at 9:43 AM
Pieris Pharmaceuticals Inc (PIRS) Given Average Rating of "Buy" by BrokeragesPieris Pharmaceuticals Inc (PIRS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 20 at 5:38 PM

SEC Filings

Pieris Pharmaceuticals (NASDAQ:PIRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pieris Pharmaceuticals (NASDAQ:PIRS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pieris Pharmaceuticals (NASDAQ PIRS) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.